Neuromuscular Centre Nijmegen, Department of Neurology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 Nijmegen HB, The Netherlands.
Neuromuscul Disord. 2011 Apr;21(4):272-8. doi: 10.1016/j.nmd.2010.12.008. Epub 2011 Jan 13.
We determined the extent of disease impact in 28 patients with genetically confirmed chronic progressive external ophthalmoplegia (CPEO) and compared the outcomes to those of matched myotonic dystrophy type I patients. CPEO patients reported a high frequency of severe fatigue (67.9%), pain (96.2%), depression (32.1%) and dependency in daily life (46.4%). The frequency and extent of depression were significantly higher than in DM1 patients (32.1% vs. 7.1%, p=0.040; mean Beck's depression inventory for primary care score 3.8±3.5 vs. 1.3±1.4, p=0.001), as were fatigue severity, pain intensity and extent of functional impairments. CPEO patients with polymerase gamma-1 mutations reported more functional impairments than those with mitochondrial DNA mutations. Disease impact was however not influenced by most clinical features. The present results help physicians to identify and to treat the factors that influence quality of life in CPEO patients and to provide symptomatic treatment where needed.
我们确定了 28 例经基因证实的慢性进行性眼外肌麻痹(CPEO)患者的疾病影响程度,并将结果与匹配的肌强直性营养不良症 I 型患者进行了比较。CPEO 患者报告严重疲劳(67.9%)、疼痛(96.2%)、抑郁(32.1%)和日常生活依赖(46.4%)的频率较高。抑郁的频率和程度明显高于 DM1 患者(32.1% vs. 7.1%,p=0.040;主要护理贝克抑郁量表平均得分为 3.8±3.5 vs. 1.3±1.4,p=0.001),疲劳严重程度、疼痛强度和功能障碍程度也是如此。与线粒体 DNA 突变相比,聚合酶γ-1 突变的 CPEO 患者报告的功能障碍更多。然而,疾病影响不受大多数临床特征的影响。目前的结果有助于医生识别和治疗影响 CPEO 患者生活质量的因素,并在需要时提供对症治疗。